Nav1.2 blockers(Sodium channel protein type II alpha subunit blockers), PI4K activators(Phosphatidylinositol 4-kinase activators), SIRT1 stimulants(NAD-dependent deacetylase sirtuin 1 stimulants)

+ [2]

Therapeutic Areas

NeoplasmsNervous System DiseasesCardiovascular Diseases+ [2]

Active Indication

Reperfusion InjuryBreast CancerAlzheimer Disease

Inactive Indication

Hepatocellular Carcinoma

Originator Organization

Beijing Xinliheng Medical Technology Development Co., Ltd.

Active Organization

Chungnam National University College of Medicine

Daejeon UniversityYonsei University College of Medicine

+ [2]

Inactive Organization

Beijing Xinliheng Medical Technology Development Co., Ltd.

Jilin University Zhengyuan Information Technologies Co., Ltd.

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure

Molecular FormulaC42H72O13

InChIKeyRWXIFXNRCLMQCD-JBVRGBGGSA-N

CAS Registry14197-60-5

100 Clinical Results associated with 20(S)-Ginsenoside-Rg3

100 Translational Medicine associated with 20(S)-Ginsenoside-Rg3

100 Patents (Medical) associated with 20(S)-Ginsenoside-Rg3

809

Literatures (Medical) associated with 20(S)-Ginsenoside-Rg3

01 Jan 2025·Journal of Ethnopharmacology

Integrated anti-fatigue effects of polysaccharides and small molecules coexisting in water extracts of ginseng: Gut microbiota-mediated mechanisms

Article

Author: Kong, Ming ; Zeng, Zhen ; Xu, Jin-Di ; Chen, Lin-Xia ; Zhou, Jing ; Shen, Hong ; Li, Song-Lin ; Zhou, Shan-Shan ; Long, Fang ; Wu, Cheng-Ying ; Mao, Qian ; Sun, Zhe

ETHNOPHARMACOLOGICAL RELEVANCEBoth clinical and animal studies have demonstrated that ginseng has curative effects on fatigue. Our previous study found that water extracts of ginseng (WEG) could significantly mitigate exercise-induced fatigue (EF). Notably, polysaccharides (GP) and small molecules (GS, mainly ginsenosides) coexist in WEG. Whether and how GP and GS contribute to the anti-EF effects of WEG remains unknown.AIM OF THE STUDYTo evaluate the contribution of GP and GS to the anti-EF effects of WEG and clarify the potential gut microbiota-mediated mechanisms.MATERIALS AND METHODSFirstly, the anti-EF effects of WEG, GP and GS were comparatively investigated by determining fatigue phenotypes (energy metabolism and oxidative stress parameters), gut microbiota composition as well as exogenous and endogenous metabolites in EF modeling rats. Then, the gut microbiota mediated mechanisms were verified by antibiotics (ABX) intervention and fecal microbial transplantation (FMT).RESULTSGP, GS and WEG each exhibited distinct anti-EF effects in differentially improving EF-induced energy metabolism abnormality and oxidative stress, reshaping gut microbiota composition, and elevating systemic metabolites. Notably, WEG showed stronger anti-EF effects than both GP and GS, characterized by better alleviation of disturbances in energy metabolism (e.g. Glc) and oxidative stress parameters (e.g. SOD), regulation of gut microbiota homeostasis (e.g. enriching the genus Coprococcus and species Collinsella provencensis etc.), as well as increases in exogenous secondary ginsenosides (e.g. 20(S)-Rg₃, 20(R)-Rg₃, CK), endogenous bile acids (BAs) (e.g. CA, DCA, LCA), and short chain fatty acids (SCFAs) (e.g. butyric acid). The stronger anti-EF effects of WEG compared to GP and GS could be abolished by ABX intervention, and transferred by FMT.CONCLUSIONGP and GS could collectively contribute to the anti-EF effects of WEG through integrated actions. Gut microbiota mediate the integrated anti-EF effects of GP and GS in WEG, potentially by regulating the levels of exogenous bioactive secondary ginsenosides, as well as endogenous BAs and SCFAs, thereby alleviating fatigue-related energy metabolic abnormalities and oxidative stress.

01 Jan 2025·Journal of Ethnopharmacology

Preconditioning with Ginsenoside Rg3 mitigates cardiac injury induced by high-altitude hypobaric hypoxia exposure in mice by suppressing ferroptosis through inhibition of the RhoA/ROCK signaling pathway

Article

Author: Chen, Qian ; He, Yacong ; Liu, Junling ; Han, Yue ; Wang, Yilan ; Shen, Zherui ; Zhao, Sijing ; Pei, Caixia ; Shi, Shihua ; Wang, Zhenxing ; Jia, Nan ; Huang, Demei ; Wu, Yongcan

ETHNOPHARMACOLOGICAL RELEVANCEGinseng has historically been utilized as a conventional herbal remedy and dietary supplement to enhance physical stamina and alleviate fatigue. The primary active component of Ginseng, Ginsenoside Rg3 (GS-Rg3), possesses diverse pharmacological properties including immune modulation and anti-inflammatory effects. Furthermore, GS-Rg3 has demonstrated efficacy in mitigating tissue and organ damage associated with metabolic disorders such as hypertension, hyperglycemia, and hyperlipidemia. Nevertheless, its potential impact on high-altitude cardiac injury (HACI) remains insufficiently explored.AIM OF THE STUDYThe aim of this study was to examine the potential cardioprotective effects of Ginsenoside Rg3, and to investigate how Ginsenoside Rg3 preconditioning can enhance high-altitude cardiac injury by inhibiting the RhoA/ROCK pathway and ferroptosis in cardiac tissue. The findings of this study may contribute to the development of novel therapeutic strategies using traditional Chinese medicine for high-altitude cardiac injury, based on experimental evidence.MATERIALS AND METHODSA hypobaric hypoxia chamber was employed to simulate hypobaric hypoxia conditions equivalent to an altitude of 6000 m. Through a randomization process, groups of six male mice were assigned to receive either saline, Ginsenoside Rg3 at doses of 15 mg/kg or 30 mg/kg, or lysophosphatidic acid (LPA) at 1 mg/kg. The impact of Ginsenoside Rg3 on high altitude-induced arrhythmias was evaluated using electrocardiography. Cardiac pathology sections stained with hematoxylin and eosin were evaluated for damage, with the extent of cardiomyocyte damage observed via transmission electron microscopy. The impact of Ginsenoside Rg3 on high-altitude cardiac injury was investigated through analysis of serum biomarkers for cardiac injury (CK-MB, BNP), inflammatory cytokines (TNF, IL-6, IL-1β), reactive oxygen species (ROS) and glutathione (GSH). The expression levels of hypoxia and hypoxia-related proteins in myocardial tissues from each experimental group were assessed using Western blot analysis. Following a review of the existing literature, the traditional regulatory mechanisms of ferroptosis were examined. Immunofluorescence staining of cardiac tissues and Western blotting techniques were utilized to investigate the impact of Ginsenoside Rg3 on cardiomyocyte ferroptosis through the RhoA/ROCK signaling pathway under conditions of hypobaric hypoxia exposure.RESULTSPre-treatment with Ginsenoside Rg3 improved high altitude-induced arrhythmias, reduced cardiomyocyte damage, decreased cardiac injury biomarkers and inflammatory cytokines, and lowered the expression of hypoxia-related proteins in myocardial tissues. Both Western blotting and immunofluorescence staining of cardiac tissues demonstrated that exposure to high-altitude hypobaric hypoxia results in elevated expression of ferroptosis and proteins related to the RhoA/ROCK pathway. Experimental validation corroborated that the role of the RhoA/ROCK signaling pathway in mediating ferroptosis.CONCLUSIONSThe findings of our study suggest that preconditioning with Ginsenoside Rg3 may attenuate cardiac injury caused by high-altitude hypobaric hypoxia exposure in mice by inhibiting ferroptosis through the suppression of the RhoA/ROCK signaling pathway. These findings contribute to the current knowledge of Ginsenoside Rg3 and high-altitude cardiac injury, suggesting that Ginsenoside Rg3 shows potential as a therapeutic agent for high-altitude cardiac injury.

01 Dec 2024·Food Science and Biotechnology

The protective effect of 20(S)-ginsenoside Rg3 on the human retinal pigment epithelial cells against hydrogen peroxide-induced oxidative stress

Article

Author: Kim, Jisu ; Min, Hyeyoung ; Kim, Ki-Uk ; Kim, Bo Kyeong ; Jang, Hyunjun

Ginsenosides, constituting 2-3% of Panax ginseng Meyer, are noteworthy for their anticancer and antioxidant effects. Despite demonstrating promise in various diseases, their specific impact on age-related macular degeneration (AMD) remains unclear. This research investigates whether ginsenosides can inhibit the progression of dry AMD and explores the mechanisms by which they influence apoptosis, providing insight into their regulatory role in programmed cell death. Human retinal pigment epithelial (ARPE-19) cells were pre-treated with ginsenosides, followed by induction of oxidative stress using hydrogen peroxide. Pre-treatment with 20(S)-ginsenoside Rg3 significantly increased cell viability and reduced apoptotic markers, including Annexin V, Bax, Bim S, cleaved caspase 3, cleaved caspase 9, and cleaved PARP. Furthermore, 20(S)-ginsenoside Rg3 effectively diminished the activation of the ERK and NF-κB signaling pathways. 20(S)-ginsenoside Rg3 could be a good prevention for AMD by modulating apoptosis, offering valuable therapeutic insights for AMD.

100 Deals associated with 20(S)-Ginsenoside-Rg3

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Reperfusion Injury	Preclinical	KR	Chungnam National University College of Medicine	01 Apr 2024
Reperfusion Injury	Preclinical	KR	Daejeon University	01 Apr 2024
Breast Cancer	Preclinical	KR	Yonsei University College of Medicine	15 Apr 2011
Breast Cancer	Preclinical	KR	Yonsei University	15 Apr 2011
Alzheimer Disease	Preclinical	-	Unigene Laboratories, Inc.	-
Hepatocellular Carcinoma	Discovery	CN	Beijing Xinliheng Medical Technology Development Co., Ltd.	01 Oct 2004
Hepatocellular Carcinoma	Discovery	CN	Jilin University Zhengyuan Information Technologies Co., Ltd.	01 Oct 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

20(S)-Ginsenoside-Rg3

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation